126 related articles for article (PubMed ID: 8312578)
1. Intrapleural adaptive immunotherapy for breast cancer patients with cytologically-confirmed malignant pleural effusions: an analysis of 67 patients in Kyoto and Shiga Prefecture, Japan.
Kan N; Kodama H; Hori T; Takenaka A; Yasumura T; Kato H; Ogawa H; Mukaihara S; Kudo T; Ohsumi K
Breast Cancer Res Treat; 1993 Sep; 27(3):203-10. PubMed ID: 8312578
[TBL] [Abstract][Full Text] [Related]
2. [Intrapleural treatment of breast cancer patients with pleural effusions: an analysis of 13 institutes in Kyoto and Shiga Prefectures. Kyoto and Shiga Breast Cancer Study Group].
Kan N; Kodama H; Hori T; Takenaka A; Yasumura T; Kato H; Ogawa H; Ohsumi K; Kudo N; Mukaihara S
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1632-5. PubMed ID: 1530322
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK-432, and IL2-cultured effusion lymphocytes to breast cancer patients with malignant pleural effusion.
Hori T; Mise K; Kan N; Okino T; Satoh K; Yamasaki S; Teramura Y; Harada T; Ohgaki K; Kodama H
Biotherapy; 1992; 5(1):21-9. PubMed ID: 1389900
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of 5-year survival among breast cancer patients with malignant pleural effusion receiving intrapleural OK-432 followed by adoptive transfer with cultured effusion lymphocytes].
Kan N
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1559-61. PubMed ID: 14619463
[TBL] [Abstract][Full Text] [Related]
5. [Intrapleural administration with OK-432 and cultured autologous pleural effusion lymphocytes for breast cancer patients with malignant pleural effusions: analysis of 84 patients over a 14-year period].
Kan N
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1796-800. PubMed ID: 10560397
[TBL] [Abstract][Full Text] [Related]
6. Influence of lymphocytes in malignant pleural effusion on the therapeutic efficacy of intrapleural OK-432 in lung cancer patients.
Shimizu T; Takahashi N; Terakado M; Akusawa H; Tsujino I; Horie T
Intern Med; 2006; 45(11):715-20. PubMed ID: 16819251
[TBL] [Abstract][Full Text] [Related]
7. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial.
Luh KT; Yang PC; Kuo SH; Chang DB; Yu CJ; Lee LN
Cancer; 1992 Feb; 69(3):674-9. PubMed ID: 1309678
[TBL] [Abstract][Full Text] [Related]
8. Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes.
Yamaguchi Y; Miyahara E; Ohshita A; Kawabuchi Y; Ohta K; Shimizu K; Minami K; Hihara J; Sawamura A; Toge T
Br J Cancer; 2003 Nov; 89(10):1876-84. PubMed ID: 14612896
[TBL] [Abstract][Full Text] [Related]
9. Combined immunotherapy with intracavital injection of activated lymphocytes, monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion.
Morisaki T; Matsumoto K; Kuroki H; Kubo M; Baba E; Onishi H; Tasaki A; Nakamura M; Inaba S; Katano M
Anticancer Res; 2003; 23(6a):4459-65. PubMed ID: 14666734
[TBL] [Abstract][Full Text] [Related]
10. Bone metastasis as a prognostic factor in breast cancer patients with liver metastasis given OK-432-combined adoptive immunotherapy via the hepatic artery.
Kan N; Yamasaki S; Kodama H; Okino T; Ichinose Y; Moriguchi Y; Li L; Sugie T; Imamura M
Biotherapy; 1993; 6(4):245-50. PubMed ID: 8018445
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy.
Yamasaki S; Okino T; Kan N; Satoh K; Mise K; Teramura Y; Harada T; Kodama H; Hori T; Ohgaki K
J Cancer Res Clin Oncol; 1992; 118(2):157-62. PubMed ID: 1735736
[TBL] [Abstract][Full Text] [Related]
12. OK-432-combined adoptive immunotherapy as a prognostic factor in peritoneal metastasis from gastric cancer.
Mise K; Kan N; Okino T; Moriguchi Y; Harada T; Ichinose Y; Inoue K
Surg Today; 1994; 24(1):54-8. PubMed ID: 8054776
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of intrapleural OK-432 and cisplatin for malignant pleural effusion in lung cancer patients].
Shimizu T; Takahashi N; Terakado M; Sato M; Sugane T; Kisohara A; Akusawa H; Tsujino I; Horie T
Gan To Kagaku Ryoho; 2005 Aug; 32(8):1139-43. PubMed ID: 16121916
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of long-term (5-year) survival in patients with metastatic breast cancer to the liver].
Kan N
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1780-4. PubMed ID: 17212106
[TBL] [Abstract][Full Text] [Related]
15. Treating carcinomatous pleural effusion by intrapleural injection of OK-432 in patients with non-small-cell lung cancer.
Chao TY; Hwang WS
Zhonghua Yi Xue Za Zhi (Taipei); 1993 Oct; 52(4):229-34. PubMed ID: 8258114
[TBL] [Abstract][Full Text] [Related]
16. Intrapleural administration of OK432 in cancer patients: augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes.
Uchida A; Micksche M; Hoshino T
Cancer Immunol Immunother; 1984; 18(1):5-12. PubMed ID: 6333269
[TBL] [Abstract][Full Text] [Related]
17. Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion.
Nio Y; Nagami H; Tamura K; Tsubono M; Nio M; Sato M; Kawabata K; Hayashi H; Shiraishi T; Imai S; Tsuchitani T; Mizuta J; Nakagawa M; Fukumoto M
Br J Cancer; 1999 May; 80(5-6):775-85. PubMed ID: 10360655
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant immunotherapy with intrapleural Streptococcus pyogenes (OK-432) in lung cancer patients after resection.
Lee YC; Luh SP; Wu RM; Lee CJ
Cancer Immunol Immunother; 1994 Oct; 39(4):269-74. PubMed ID: 7954529
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515.
Yoshida K; Sugiura T; Takifuji N; Kawahara M; Matsui K; Kudoh S; Takada M; Fukuoka M; Ariyoshi Y; Fukuda H; Saijo N
Lung Cancer; 2007 Dec; 58(3):362-8. PubMed ID: 17716779
[TBL] [Abstract][Full Text] [Related]
20. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
Kan N; Okino T; Nakanishi M; Sato K; Mise K; Teramura Y; Yamasaki S; Hori T; Ohgaki K; Tobe T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
